Issue on combined locoregional and systemic treatment for hepatocellular carcinoma

Abstract

Treatment for hepatocellular carcinoma (HCC) has been challenging as most patients present with late, advanced disease, where curative options are limited. For years, locoregional therapy (LRT) has been the first-line therapy for intermediate-stage HCC and sorafenib for advanced HCC. However, these treatments are often palliative since they are plagued by tumor recurrence or progression. Therefore, there is growing interest in combined therapy to utilize their respective strengths to produce synergistic effects. This review outlines past and current research on the efficacy and safety of combined LRT and systemic therapy.

Keywords

Hepatocellular carcinoma / systemic therapy / locoregional therapy

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[3] Livraghi T,Di Stasi M.Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.Hepatology2008;47:82-9

[4] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[5] National Comprehensive Cancer Network. Hepatocellular cancer (Version 5.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf [Last accessed on 10 Mar 2023]

[6] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.Hepatology2003;37:429-42

[7] Raza A.Hepatocellular carcinoma review: current treatment, and evidence-based medicine.World J Gastroenterol2014;20:4115-27 PMCID:PMC3989948

[8] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[9] Cheng AL,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[10] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.J Hepatol2022;76:681-93

[11] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[12] Abou-alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evidence2022;1

[13] Sergio A,Cardin R.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.Am J Gastroenterol2008;103:914-21

[14] Li X,Zheng CS,Liu X.Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.World J Gastroenterol2004;10:2878-82 PMCID:PMC4572123

[15] Chen L,Yang X.Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: current status.Cancer Lett2016;370:78-84 PMCID:PMC4686130

[16] Oliveri RS,Gluud C.Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma.Cochrane Database Syst Rev2011;(3):CD004787

[17] Paul SB.Role of transcatheter intra-arterial therapies for hepatocellular carcinoma.J Clin Exp Hepatol2014;4:S112-21 PMCID:PMC4284218

[18] Miller FH,Gabr A.Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review.Radiographics2021;41:1802-18

[19] Ahmed A,LeGout JD.The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure.J Gastrointest Oncol2021;12:751-61 PMCID:PMC8107583

[20] Lewandowski RJ,Abouchaleh N.Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology2018;287:1050-8

[21] Song MJ.Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma.World J Gastroenterol2015;21:3843-9 PMCID:PMC4385530

[22] Li S,Han X.Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis.J Vasc Interv Radiol2021;32:1267-1276.e1

[23] Lyu N,Li JB.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1).J Clin Oncol2022;40:468-80

[24] Bteich F.Current and future systemic therapies for hepatocellular carcinoma.Gastroenterol Hepatol (NY)2019;15:266-72 PMCID:PMC6589844

[25] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[26] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[27] Rizzo A,Novelli M,Scioscio VD.Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.Ther Adv Med Oncol2020;12:1758835920936932 PMCID:PMC7343359

[28] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[29] Zhu AX,Yen CJ.REACH-2 study investigatorsRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[30] Gordan JD,Abou-Alfa GK.Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.J Clin Oncol2020;38:4317-45

[31] Gao X,Wang Y.Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four prognostic and immunotherapeutically relevant subclasses.Front Oncol2020;10:610513 PMCID:PMC7933665

[32] Yau T,Finn RS.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022;23:77-90

[33] Rizzo A,Di Federico A.Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: Where do we stand?.Front Oncol2021;11:803133 PMCID:PMC8718608

[34] Fukuda H,Moriya S.Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis.Radiology2014;272:598-604

[35] Feng X,Du X.Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.Am J Gastroenterol2014;109:1891-9

[36] Kan X,Wan QY,Han M,Zhu M,Liu KH.Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.Eur Rev Med Pharmacol Sci2015;19:247-55

[37] Bruix J,Mazzaferro V.STORM investigatorsAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol2015;16:1344-54 PMCID:PMC8628622

[38] Jin M,Liu Y,Fu X.Safety and efficacy of physical thermal ablation combined sorafenib for hepatocellular carcinoma: a meta-analysis.J Clin Transl Hepatol2021;9:149-159 PMCID:PMC8111114

[39] Wang F,Komiyama S.Combination therapy with lenvatinib and radiofrequency ablation for patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh class a liver function: a pilot study.Front Oncol2022;12:843680 PMCID:PMC9114706

[40] Cui J,Zhao H.Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.Int J Cancer2014;134:342-51

[41] Bian H,Nan G.Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.J Natl Cancer Inst2014;106:dju239

[42] Lee JH,Lim YS.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology2015;148:1383-91.e6

[43] Lee JH,Lim YS.Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.Cancer Immunol Immunother2019;68:23-32 PMCID:PMC6326973

[44] Wang X,Chen S.Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis.Int J Hyperthermia2021;38:1519-28

[45] Ricke J,Amthauer H.Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019;71:1164-74

[46] Kaseb AO,Lee SS.A Prospective phase II study of safety and efficacy of sorafenib followed by ⁹⁰Y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:1129-45 PMCID:PMC8437411

[47] Zhan C,Shanbhogue KP.Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma.J Vasc Interv Radiol2020;31:25-34

[48] Fenton SE,Mulcahy MF.A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.JCO2021;39:e16183-e16183

[49] Tai D,Gogna A.Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.Lancet Gastroenterol Hepatol2021;6:1025-35

[50] Bruix J,Sherman M.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.J Hepatol2012;57:821-9

[51] Kudo M,Chida N.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.Eur J Cancer2011;47:2117-27

[52] Sansonno D,Russi S,Sansonno L.Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.Oncologist2012;17:359-66 PMCID:PMC3316921

[53] Lencioni R,Han G.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial.J Hepatol2016;64:1090-8

[54] Meyer T,Ma YT.Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol2017;2:565-75

[55] Erhardt A,Dollinger M.TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.Cancer Chemother Pharmacol2014;74:947-54

[56] Chao Y,Han G.The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.Int J Cancer2015;136:1458-67

[57] Park JW,Kim HB.Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.J Hepatol2012;56:1336-42

[58] Kudo M,Ikeda M on behalf of the TACTICS study group.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Gut2020;69:1492-1501 PMCID:PMC7398460

[59] Park JW,Kim DY.Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial.J Hepatol2019;70:684-91

[60] Bonifazi M,Moja L.Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.Oncologist2012;17:117-24 PMCID:PMC3267810

[61] Finn RS,Britten CD,Busuttil RW.Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.Liver Int2009;29:284-90

[62] Fang P,Cheng ZG,Wang JL.Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.PLoS One2012;7:e49717 PMCID:PMC3526612

[63] Britten CD,Wainberg ZA.Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.BMC Cancer2012;12:16 PMCID:PMC3292503

[64] Fu Z,Zhong J.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.Hepatol Int2021;15:663-75 PMCID:PMC8286947

[65] Finn RS,Zhu AX.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.J Clin Oncol2020;38:2960-70 PMCID:PMC7479760

[66] Rini BI,Tomczak P.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.Lancet2011;378:1931-9

[67] Chan SL,Mo F.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.Cancer2017;123:3977-85

[68] Kang YK,Park JW.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.Ann Oncol2015;26:2457-63

[69] Kudo M,Finn RS.Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial.Hepatology2014;60:1697-707

[70] Kudo M,Park JW.Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet Gastroenterol Hepatol2018;3:37-46

[71] Duffy AG,Makorova-Rusher O.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol2017;66:545-51 PMCID:PMC5316490

[72] Ji Q,Zhu X,Ling C.Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma.J BUON2021;26:235-242

[73] Viveiros P,Lewandowski RJ.Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC).Cancers (Basel)2019;11:1085 PMCID:PMC6721343

[74] Ikeda M,Sato T.Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.Ann Oncol2016;27:2090-6 PMCID:PMC5091321

[75] Kim BK,Byun HK.Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma: a prospective phase 2 trial.Int J Radiat Oncol Biol Phys2020;107:106-15